trending Market Intelligence /marketintelligence/en/news-insights/trending/dM1hE_akFHUcLAQddVQKmA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

European Commission approves Biogen's spinal muscular atrophy drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

European Commission approves Biogen's spinal muscular atrophy drug

Biogen Inc. received marketing authorization approval from the European Commission for Spinraza, a drug to treat 5q spinal muscular atrophy, a genetic neuromuscular disorder.

Spinal muscular atrophy is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness.

The drug is the first approved treatment in the EU for spinal muscular atrophy. It was reviewed under the European Medicines Agency's accelerated assessment program, intended to expedite access to patients with unmet medical needs.

Spinraza's approval is primarily based on data from two trials, both of which demonstrated the clinically meaningful efficacy and favorable benefit-risk profile of the drug.

The timing of the drug's availability in the EU will vary by country, per local reimbursement and access pathways.

Biogen has also submitted regulatory filings in Japan, Canada, Australia, Switzerland and Brazil and plans to initiate additional filings in other countries in 2017.